




Expert UK-based CRO offering customised bioassay development, pharmacological profiling and compound screening

### Welcome to the latest edition of our newsletter

As we battle COVID-19 in these difficult times, we at Aurelia Bioscience would like to inform our readers that our labs are still operational as usual and we are taking full precautionary measures as per the UK government's policy. Whilst the lockdown is still in place, we would like to take this opportunity to share some blogs, posters and presentations with our science enthusiasts:

### Blog: PROTAC Assays- Successfully measuring Protein Degradation

PROTAC (PROteolysis TArgeting Chimera) is one of the hottest topics in drug discovery today as it is a highly promising new approach to targeted therapy. It offers several advantages over traditional occupancy-based drugs, with a potential to target the 'undruggable' proteome. *Follow the link to read the full blog:* <https://www.aureliabio.com/news/blog-protac-assays-successfully-measuring-protein-degradation/>



## Webinar: Cell-based screening: Old dogs with new tricks

Medicines Discovery Catapult is hosting a series of informative webinars covering the drug discovery process from 22<sup>nd</sup> April all the way up to 17<sup>th</sup> June. Our CSO, Dr Gary Allenby will be talking on 'Cell-based screening: Old dogs with new tricks' on Wednesday, 29th April at 2pm. Contact us to learn more: [info@aureliabio.com](mailto:info@aureliabio.com)



**Cell-based screening:  
Old dogs with new tricks**

❖ **Wednesday, 29th April at 2pm**


## New recruit: Amy Kerry, Research Scientist

Amy is the newest member of the Aurelia Bioscience team. Her role involves bioassay development and compound screening for client projects. With a background in molecular biology and experience in clinical pharmacology, she is particularly fond of cell-based assays and tissue culture. Amy not only loves exploring different research areas and specialised techniques in the lab, but also enjoys analysing data for the clients thereafter. "I am very excited to be a part of the Aurelia Bioscience family. I look forward to learning from the experience of my colleagues and contributing to the drug discovery journey of our clients", says Amy with a big smile on her face as she begins to settle in her new role.



## SLAS 2020: Boston, USA

Aurelia Bioscience exhibited and presented posters at the 'SLAS 2020' conference in Boston, USA in January. Follow the link to download the posters: <https://www.aureliabio.com/publications-tech/publications-articles-posters/>



**Contact Information:**

Aurelia Bioscience  
BioCity Nottingham,  
Pennyfoot Street,  
Nottingham NG1 1GF  
United Kingdom

Phone: +44 (0)115 837 0503

Email: [info@aureliabio.com](mailto:info@aureliabio.com)

Web: [www.aureliabio.com](http://www.aureliabio.com)